Clinical Trials

The purpose of this study is to evaluate different strategies of cardiovascular therapy with Carvedilol, aiming to reduce the incidence of left ventricular ejection fraction (LVEF) decline and heart failure (HF) in patients undergoing curative intent Trastuzumab for breast cancer.

.

The purpose of this study is to evaluate the probable benefit and safety of the LIPOSORBER® LA-15 System for the treatment of adult and pediatric patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when the standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 45 ml/min/1.73m2, or the patient is post renal transplantation. Treatment for FSGS is considered unsuccessful if the patient is unresponsive to standard therapy (e.g., at least 8 weeks of corticosteroids) and fails to achieve complete or partial remission. A standard treatment is considered not well tolerated if the patient experiences severe side effects without providing an acceptable level of clinical benefit.

The purpose of this study is to obtain adipose tissue from patients undergoing vascular surgery where EVs can be isolated from the fat and used for research purposes to examine their effect on inflammation and remodeling in culture and in animal models. The samples will immediately be processed to obtain EVs for research purposes - this is not a biorepository. 

The purpose of this research is to study immune cells called T cells and monocytes (types of blood cells that fight infection and can also cause autoimmune disease) that may damage heart tissue during myocarditis (inflammation of the heart muscle). Cytokines (proteins that send signals between cells) found in the blood will be studied for their effects on blood immune cells to better understand how they can lead to heart failure during and after myocarditis.

The purpose of this study is to evaluate the use of virtual reality (VR) technology as adjunct to routine anesthesia care for patients undergoing electrophysiology (EP) procedures.

Aims, purpose, or objectives:

1. Develop a retrospective registry of patients with cardiac sarcoidosis
2. Develop a prospective registry of patients with cardiac sarcoidosis
3. Understand the natural history of cardiac sarcoidosis through evaluation of outcomes of patients in the registry
4. Determine risk factors for sarcoid involvement of the heart
5. Evaluate outcomes of patients both treated and untreated with cardiac sarcoidosis
6. Understand the complications of untreated and treated cardiac sarcoidosis

The objectives of this study are to measure and improve quality of care (including assessing differences in adherence to evidence-based guidelines and establishing benchmarks for health outcomes); determine the clinical effectiveness, comparative effectiveness, and cost effectiveness of treatment approaches; understand risk factors for outcomes and regional/center differences; and facilitate funded clinical trials of new therapies and collaboration with the PAH community at large, including providers, patients, and their caregivers.

The purpose of this study is to establish a registry that will address the data gap regarding the course of NSTEMI (Non-ST-Elevation Myocardial Infarction) between ED (Emergency Department) arrival and diagnostic angiography in detail, by characterizing and following the ED and peri-ED use of advanced OAP (Oral Anti-Platelet) agents. In addition to exploring ED treatment patterns and success of both ischemic and bleeding risk stratification prior to definition of the coronary anatomy, data generated via the UPSTREAM registry will allow plausible attribution of ischemic and bleeding outcomes to pre-catheterization antiplatelet therapy in the management of NSTEMI. This registry further seeks to demonstrate that contemporary use of upstream ticagrelor is associated with an economically-sound utilization of hospital resources, and smooth transition of care into the outpatient, secondary prevention setting for the first 30 days after hospitalization. Finally, it will allow characterization of patient selection factors and processes for ticagrelor vs alternative OAP agents, carrying out that descriptive comparison through discharge. Patients transferred in to an UPSTREAM hospital are eligible for inclusion, but the timing for OAP agent administration and diagnostic catheterization begin with ED care at the first hospital.

The purpose of this study is to describe the incidence and type of arrhythmia seen in patients with Eisenmenger syndrome, to define predisposing factors potentially leading to the onset of arrhythmia, and to describe the influence of arrhythmia on outcomes.

The purpose of this study is to determine whether serum biomarkers and comorbidities differ between subjects with hEDS/HSD vs. other non-hypermobile EDS subtypes and whether sex and/or age differences exist, and to determine whether serum biomarkers and comorbidities differ between subjects with hEDS vs. HSD and whether sex and/or age differences exist.